Literature DB >> 27869496

A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma.

M Elshaer1, G Gravante2, M Kosmin3, A Riaz4, A Al-Bahrani4.   

Abstract

BACKGROUND Pancreatic ductal adenocarcinoma is the most common pancreatic cancer. Five-year overall survival is currently 3.3-6.0%. The aim of this review was to evaluate the prognostic value of lymph node ratio, number of positive nodes and total nodes examined on overall survival rate following pancreatic resection. MATERIALS AND METHODS A literature search was conducted of MEDLINE, EMBASE, the Cochrane Library and Central Register of Controlled Trials and the Cochrane Database of Systematic Review databases, from January 1996 to January 2016. RESULTS Overall, 19 studies including 4,883 patients examined the relationship between lymph node ratio and overall survival. A high lymph node ratio was associated with decreased overall survival in 17 studies. A total of 12 studies examined the relationship between the number of positive nodes and overall survival, and 11 studies revealed that an increase in the number of positive nodes was associated with decreased overall survival. In 15 studies examining the relationship between the total nodes examined and overall survival, there was no association with overall survival in 12 studies. CONCLUSIONS Lymph node ratio and number of positive nodes are factors associated with overall survival in pancreatic ductal adenocarcinoma, but not total nodes examined.

Entities:  

Keywords:  Lymph Node Ratio; Lymph Node Status; Pancreatic Cancer; Survival

Mesh:

Year:  2016        PMID: 27869496      PMCID: PMC5392844          DOI: 10.1308/rcsann.2016.0340

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  35 in total

1.  Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field transthoracic esophagectomy.

Authors:  Justin K Smit; Bareld B Pultrum; Hendrik M van Dullemen; Gooitzen M Van Dam; Henk Groen; John T M Plukker
Journal:  Am J Surg       Date:  2010-04-20       Impact factor: 2.565

2.  Evaluation of the prognostic value of the metastatic lymph node ratio for gastric cancer.

Authors:  Bao-Yan Zhang; Jing Yuan; Zhen-Shuang Cui; Zhong-Wu Li; Xiang-Hong Li; You-Yong Lu
Journal:  Am J Surg       Date:  2013-10-12       Impact factor: 2.565

3.  Lymph node ratio and breast cancer prognosis: a meta-analysis.

Authors:  Dechun Liu; Yanbin Chen; Miao Deng; Gangqiang Xie; Jianguang Wang; Like Zhang; Qipeng Liu; Pengfei Yuan; Xiaoshan Feng
Journal:  Breast Cancer       Date:  2013-10-08       Impact factor: 4.239

4.  Prognostic assessment of different lymph node staging methods for pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds of positive lymph nodes.

Authors:  Marco La Torre; Giuseppe Nigri; Niccolò Petrucciani; Marco Cavallini; Paolo Aurello; Giulia Cosenza; Genoveffa Balducci; Vincenzo Ziparo; Giovanni Ramacciato
Journal:  Pancreatology       Date:  2014-06-14       Impact factor: 3.996

5.  Reappraisal of Nodal Staging and Study of Lymph Node Station Involvement in Pancreaticoduodenectomy with the Standard International Study Group of Pancreatic Surgery Definition of Lymphadenectomy for Cancer.

Authors:  Giuseppe Malleo; Laura Maggino; Paola Capelli; Francesco Gulino; Silvia Segattini; Aldo Scarpa; Claudio Bassi; Giovanni Butturini; Roberto Salvia
Journal:  J Am Coll Surg       Date:  2015-02-28       Impact factor: 6.113

6.  Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer.

Authors:  Han-xiang Zhan; Jian-wei Xu; Lei Wang; Guang-yong Zhang; San-yuan Hu
Journal:  World J Surg Oncol       Date:  2015-03-13       Impact factor: 2.754

7.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21

8.  53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma.

Authors:  Natalie L Ausborn; Tong Wang; Sabrina C Wentz; Mary Kay Washington; Nipun B Merchant; Zhiguo Zhao; Yu Shyr; Anuradha Bapsi Chakravarthy; Fen Xia
Journal:  BMC Cancer       Date:  2013-03-26       Impact factor: 4.430

9.  Survival from cancer of the pancreas in England and Wales up to 2001.

Authors:  E Mitry; B Rachet; M J Quinn; N Cooper; M P Coleman
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

10.  Prognostic impact of the metastatic lymph node ratio on survival in rectal cancer.

Authors:  Wafi Attaallah; Omer Gunal; Manuk Manukyan; Gulden Ozden; Cumhur Yegen
Journal:  Ann Coloproctol       Date:  2013-06-30
View more
  22 in total

1.  Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study.

Authors:  Christof Kaltenmeier; Ibrahim Nassour; Richard S Hoehn; Sidrah Khan; Alison Althans; David A Geller; Alessandro Paniccia; Amer Zureikat; Samer Tohme
Journal:  J Gastrointest Surg       Date:  2020-12-02       Impact factor: 3.452

2.  Pattern, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma: how do they matter?

Authors:  Charing C N Chong
Journal:  J Vis Surg       Date:  2018-05-18

3.  Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma.

Authors:  Shayan Cheraghlou; George O Agogo; Michael Girardi
Journal:  JAMA Dermatol       Date:  2019-07-01       Impact factor: 10.282

4.  Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC).

Authors:  M Redegalli; M Schiavo Lena; M Reni; C Doglioni; M G Cangi; C E Smart; M Mori; C Fiorino; P G Arcidiacono; G Balzano; M Falconi
Journal:  Ann Surg Oncol       Date:  2022-03-01       Impact factor: 4.339

5.  Prognostic Nomogram for Resected Pancreatic Adenocarcinoma: A TRIPOD-Compliant Retrospective Long-Term Survival Analysis.

Authors:  Dong Xu; Kai Zhang; Mingna Li; J P Neoptolemos; Junli Wu; Wentao Gao; Pengfei Wu; Baobao Cai; Jie Yin; Guodong Shi; Zipeng Lu; Kuirong Jiang; Yi Miao
Journal:  World J Surg       Date:  2020-04       Impact factor: 3.352

6.  Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer-patterns of care and overall survival.

Authors:  Michael J Dohopolski; Scott M Glaser; John A Vargo; Goundappa K Balasubramani; Sushil Beriwal
Journal:  J Gastrointest Oncol       Date:  2017-10

7.  Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL.

Authors:  Androulla Elia; Ricky Henry-Grant; Charlotte Adiseshiah; Catherine Marboeuf; Rebecca J Buckley; Michael J Clemens; Satvinder Mudan; Stéphane Pyronnet
Journal:  Cell Death Dis       Date:  2017-12-12       Impact factor: 8.469

8.  Association of RAB5 overexpression in pancreatic cancer with cancer progression and poor prognosis via E-cadherin suppression.

Authors:  Takamichi Igarashi; Kenichiro Araki; Takehiko Yokobori; Bolag Altan; Takahiro Yamanaka; Norihiro Ishii; Mariko Tsukagoshi; Akira Watanabe; Norio Kubo; Tadashi Handa; Yasuo Hosouchi; Masahiko Nishiyama; Tetsunari Oyama; Ken Shirabe; Hiroyuki Kuwano
Journal:  Oncotarget       Date:  2017-02-14

9.  Prognostic Nomogram for patients undergoing radical Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head.

Authors:  Chao Wu; Sheng Zhong Hou; Zuowei Wu; Xing Huang; Zihe Wang; Bole Tian
Journal:  BMC Cancer       Date:  2021-05-27       Impact factor: 4.430

10.  Comparison of prognostic prediction between nomogram based on lymph node ratio and AJCC 8th staging system for patients with resected pancreatic head carcinoma: a SEER analysis.

Authors:  Ning Pu; Jianang Li; Yaolin Xu; Wanling Lee; Yuan Fang; Xu Han; Guochao Zhao; Lei Zhang; Abulimiti Nuerxiati; Hanlin Yin; Wenchuan Wu; Wenhui Lou
Journal:  Cancer Manag Res       Date:  2018-02-05       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.